Skip to main
  1. Stocks
  2. Avalo Therapeutics
  3. Forecast
AVTX

Avalo Therapeutics (AVTX) Stock Forecast & Price Target

Avalo Therapeutics (AVTX) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Avalo Therapeutics is supported by compelling clinical validation for abdakibart, with the Phase 2 LOTUS study in hidradenitis suppurativa (n=253) meeting its primary endpoint and delivering a 42.5% combined HiSCR75 response rate, the highest absolute improvement seen in trials of similar size or larger. Its differentiated profile—selective high-affinity IL-1β blockade, favorable safety, early effects on draining tunnels, and dosing potential out to Q4W—positions it as a credible later-line option even after AbbVie’s weaker-than-expected lutikizumab data. Fundamentally, the company’s positive outlook is reinforced by a well-funded balance sheet with $462.8M in cash, expected to fund operations into 2029, while Phase 3 initiation is targeted for 1H27 and could unlock significant upside in a large, underpenetrated HS market.

Bears say

Avalo Therapeutics is viewed negatively because the newly disclosed INTREPID data materially weaken confidence that IL-1 inhibition will translate into a durable competitive advantage in hidradenitis suppurativa, with an 8-point placebo-adjusted HiSCR75 benefit versus 31.4% active response and a 13-point contraction from Phase 2 driven largely by lower active-arm efficacy. That read-through directly pressures abdakibart, whose 17.2-point LOTUS result now faces the risk of similar Phase 2-to-Phase 3 erosion, while Avalo’s valuation is increasingly anchored to cash rather than pipeline value given a market cap of about $425M against $472.2M of cash and investments at June 30. The company also used $37.7M in operating cash during 1H26, guides runway into 2029, and still must fund Phase 3 initiation in 1H27 and a $10M milestone, leaving both abdakibart and AVTX-010 exposed to the same pathway risk.

Avalo Therapeutics (AVTX) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Avalo Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Avalo Therapeutics (AVTX) Analyst Forecast & Price Prediction

Get the latest Avalo Therapeutics (AVTX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Avalo Therapeutics (AVTX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Avalo Therapeutics (AVTX) Forecast

Analysts have given Avalo Therapeutics (AVTX) a Buy based on their latest research and market trends.

According to 10 analysts, Avalo Therapeutics (AVTX) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Avalo Therapeutics (AVTX)


Avalo Therapeutics (AVTX) Analyst Forecast & Price Prediction

Get the latest Avalo Therapeutics (AVTX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Avalo Therapeutics (AVTX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover AVTX stock data and trends